

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Vital Innovations Holdings Limited**

### **維太創科控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6133)**

#### **INSIDE INFORMATION**

#### **EXTENSION OF THE FIRST EXCLUSIVITY PERIOD**

#### **IN RELATION TO THE MEMORANDUM OF UNDERSTANDING OF A POSSIBLE ACQUISITION**

This announcement is made by Vital Innovations Holdings Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

References is made to the announcement (the “**Announcement**”) of the Company dated 16 December 2021 in relation to, among other things, a Possible Acquisition of the Company. Capitalised terms used in this announcement shall have the same meaning as those defined in the Announcement unless otherwise defined.

Pursuant to the MOU dated 16 December 2021, the First Exclusivity Period will fall due on 16 March 2022, being three months from the date of the MOU. Upon expiry of the First Exclusivity Period and the Company’s satisfaction with the preliminary result of the Due Diligence Review, the parties can extend the First Exclusivity Period by three months by confirmation in writing.

Although additional time is required for the Due Diligence Review, the Company and the Potential Vendor still entered into a supplemental memorandum of understanding (“**Supplemental MOU**”) on 16 March 2022 and agreed to extend the First Exclusivity Period from 16 March 2022 to 31 May 2022.

Moreover, pursuant to the MOU, the Company has to pay a further RMB5 million to the Potential Vendor as the Second Earnest Money, which is refundable if the Possible Acquisition does not proceed. According to the Supplemental MOU, both parties agreed that the Company can pay the Second Earnest Money to the Potential Vendor not later than 31 May 2022.

According to the Supplemental MOU, if the completion of the Possible Acquisition cannot be taken place on or before 30 June 2022, the Company may consider to provide a loan to the Target Company, the amount and other terms of which shall be provided in the formal agreement.

Save for the above, all other terms and conditions of the MOU shall remain unchanged and shall continue in full force and effect. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

The final terms of the definitive agreement in respect of the Possible Acquisition are subject to further negotiations between the parties and have yet to be finalised and may therefore deviate from those set out in the MOU.

**The MOU is not legally binding. The Possible Acquisition may or may not proceed. Shareholders and possible investors of the Company are reminded to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Vital Innovations Holdings Limited**  
**Rong Xiuli**  
*Chairperson*

Hong Kong, 16 March 2022

*As at the date of this announcement, the Board comprises Ms. Rong Xiuli, Mr. Rong Shengli, Mr. Yin Xuquan and Mr. Wong Ho Chun as executive Directors, and Mr. Leung Man Fai, Mr. Wong Pong Chun James and Mr. Han Xiaojing as independent non-executive Directors.*